Solos Endoscopy's MammoViewÃ‚® System Proves Crucial to Early Breast Cancer Detection
BOSTON, July 20, 2011 /PRNewswire/ -- Solos Endoscopy, Inc.'s (OTCPK: SNDY) MammoView® instrument line, designed exclusively for breast endoscopy, has become crucial to early breast cancer screening as a method to significantly reduce breast cancer death rates. The Solos MammoView® Breast Endoscopy System is designed to distinguish and inspect suspicious pre-cancerous lesions undetectable by other methods as well as complement existing diagnosis and treatment options with direct endoscopic observation.
The Solos MammoView® system is currently in use at various teaching hospitals across the United States. Patients should be aware that mammary ductoscopy, utilizing the MammoView® system, is a means to detect, diagnose, and treat breast cancer years before surgery, physical exams or other external imaging that can reveal evidence of the disease.
According to a recent report in the journal Radiology, "The Swedish Two-County Trial" was the first study to demonstrate a drop in breast cancer mortality from solely screening with mammography. Researchers found that there were 30% fewer deaths caused by breast cancer in an invitation group (received an invitation to screening), compared to the usual care group (received usual care). For breast cancer detection, other than clinical and self-examination, women rely almost exclusively on mammography, which can have limitations. Mammography fails to detect up to 20% of cancer in women over 50 and up to 40% of cancer in younger women. When cancer is detected, the technology is so insensitive that typically, the smallest tumor size detected is approximately 1cm. At that size, a tumor has probably been growing, undetected, for nearly 8 years. The findings, coupled with the limitations, are significant in that mammary ductoscopy, as capable with the Solos MammoView® system, is designed to provide physicians the means to detect, diagnose, and treat breast cancer years before surge